20 results about "Polymicrobial Infections" patented technology

This invention relates to a vulnerary multifunctional composition, based on unripe coffee cherries (peel, mucilage, beans and silverskin), seed extract of Trigonella foenum-graecum, with one or more tissue-inducing molecules derived from the secondary metabolites of both plants. The unexpected and surprising ability of this new composition to solve the problems of chronic non-healing wounds addresses a long felt unmet need in the medical arts. Through a multifaceted approach, it combats microbial infections, reduces chronic inflammation, counters oxidative stress, enhances immune responses, promotes angiogenesis, regulates protease activity, stimulates collagen deposition, increases growth factor availability, facilitates cell migration, and prevents persistent infections. These novel integrated therapies represent a breakthrough in addressing macroscopic wound healing while targeting the underlying microscale mechanisms. This invention also relates to methods for preparing, using, and administering the multifunctional composition for timely healing in mammals with various skin lesions.

The present disclosure allows for an anaerobic biofilm also known as a beneficial biofilm, to be grown on a hydrophilic substrate surface and contained within the varied surface and surface-accessible interior of the substrate. This allows for the anaerobic biofilm to remain intact and functional while being exposed to an aerobic environment. The present disclosure further allows for the constituent microbes to interact with an oxygen-rich surrounding without perishing. The present disclosure allows anaerobic biofilm constituent microbes to exist side-by-side with aerobic biofilm constituent microbes and employ various mechanisms to starve or eliminate unhealthy biofilms and sessile and free-floating unwanted microbes, and / or deliver substances to soil to improve soil health or to the body to assist in repair of injuries such as microbial infections, lesions, tumors, cuts, abrasions, burns, and nerve damage.

An application of a Bacillus Calmette-Guérin (BCG)-based outer membrane vesicle (OMV) trained immunity inducer in preparation of an immunotherapeutic drug for sepsis is provided. The disclosure isolates and collects OMVs secreted by BCG bacteria to obtain a BCG-based OMV trained immunity inducer (designated as B-OMVs). The B-OMVs combines distinct advantages of both BCG and OMVs while circumventing their respective drawbacks. The developed B-OMVs exhibits characteristics such as being non-replicative, non-infectious, and of low toxicity, resulting in minimal impact on the organism and high safety. In addition, the B-OMVs demonstrates a more moderate yet effective immunomodulatory capacity. It can induce trained immunity, enhance the body's resistance to microbial infections, reduce the need for antibiotics, and more effectively improve the prognosis of sepsis.

An infection detection medical system may include an indwelling medical device and a dedicated computing device. The indwelling medical device may include an internal conduit configured to be inserted percutaneously into the patient's blood vessels and a microcontroller integrated into part of the indwelling medical device. The microcontroller may include a chemical sensor module and one or more chemical sensors configured to generate electrical signals in response to interaction with one or more volatile organic compounds (VOCs) associated with the patient. The microcontroller may also include a microcontroller processor configured to generate chemical sensor data from the electrical signals. In addition, the dedicated computing device may include a computing device processor configured to generate one or more observed chemical signatures from the chemical sensor data and to determine whether the patient has a microbial infection by comparing one or more observed chemical signatures for a microbial infection with known chemical signatures.

This invention discloses a long-acting antipruritic and antibacterial topical skin preparation, comprising N-ethyl-γ-L-glutamine, 1-1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate-N-(L-γ-glutamyl-N-ethyl)-ethanolamine (POPE-N-Et-Gln-α), chlorhexidine acetate, and saffron extract as active ingredients, formulated into a hydrogel or cream with a pharmaceutically acceptable matrix. POPE-N-Et-Gln-α provides rapid transdermal action, while N-ethyl-γ-L-glutamine offers sustained-release and long-lasting effects; saffron extract provides anti-inflammatory and antioxidant effects, and chlorhexidine acetate provides antibacterial and antifungal effects. This invention is hormone-free and non-addictive, achieving both rapid and long-lasting antipruritic effects, and is suitable for eczema, urticaria, dry skin, neurodermatitis, psoriasis, microbial infections, and skin itching caused by insect bites.

The present disclosure provides systems and methods for detection of microbial DNA and RNA. In an aspect, a system or method for detection of microbial DNA or RNA comprises metagenomic next-generation sequencing of clinical samples (e.g., cerebral spinal fluid) to detect the microbial composition of the sample to diagnose a microbial infection (e.g., of the central nervous system).

The present invention relates to a method of treating tissue of a subject infected with a catalase-positive microorganism, the method comprising the steps of: applying light having a wavelength of about 400 nm to about 430 nm to the tissue of the subject infected with the catalase-positive microorganism, wherein catalase is inactivated, and contacting the tissue with a composition comprising a dilute peroxide solution. The present invention also relates to a device or light source for delivering light-activated pulsed light to treat tissue of a subject infected with a catalase-positive microorganism, wherein the light-activated pulsed light has a wavelength of about 400 nm to about 430 nm.

This disclosure relates to pentagalloyl glucose compositions and uses in managing microbial infections and compositions related thereto. In certain embodiments, this disclosure relates to compositions of pentagalloyl glucose. In certain embodiments, this disclosure relates to methods of treating or preventing a microbial infection, e.g., an antimicrobial resistant microbial infection, comprising administering to a subject in need thereof an effective amount of pentagalloyl glucose or salt thereof. In certain embodiments, the microbe is bacteria or fungi resistant to one or more antibiotic agents or antifungal agents.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic bacterial DNA nanomicelle, its preparation method, and its applications. By mimicking the structural and functional characteristics formed when microorganisms infect a host, exogenous nucleic acid stimulation signals and oxidative stress regulation functions are integrated into a single nanostructure. A micellar nanostructure is designed, comprising a complex of oligonucleotides containing CpG motifs and ferrocene groups, which is formed through self-assembly in solution. This nanomicelle can significantly promote the proliferation or differentiation of dendritic cells, improve their maturity, and enhance their immune activation capacity; by enhancing the cross-presentation capacity of dendritic cells to target antigens, it effectively promotes cytotoxic CD8+. + T-cell immune responses; it can also enhance the body's cellular immune response by inducing the activation and proliferation of antigen-specific cells. These DNA nanomicelles have significant clinical application value in areas such as vaccine adjuvants, tumor immunotherapy, and immune regulation.

An antimicrobial agent for use in the treatment or prevention of a bacterial infection, wherein a patient is selected for treatment using the antimicrobial agent based on the level of D-lactate in a patient sample.

To provide a compound having antibacterial activity. [Solution] The present invention relates to a novel oxazolidinone (formula I) having ring A characterized by a monocyclic, bicyclic, or spirocyclic substituent containing nitrogen. The present invention relates to TIFF2026092059000321.tif3764 or pharmaceutically acceptable salts thereof, their preparations, and their use alone or in combination with other anti-infective agents as drugs for treating Mycobacterium tuberculosis and other microbial infections. The present invention generally relates to compounds having antibacterial activity, more specifically, anti-tuberculosis properties. In particular, the present invention relates to substituted phenyloxazolidinone compounds useful for treating tuberculosis in patients requiring treatment for tuberculosis.

The application discloses a kind of liposome polypeptide vaccine of pulmonary inhalation immunity and its preparation method and application, belong to biological medicine technical field.The vaccine includes the liposome of DSPC and DDAB, polypeptide antigen and molecular adjuvant loaded therein.The optimal preparation process condition is: the mass ratio of DSPC and DDAB 5:1, ultrasonic power 275 W, ultrasonic number 50 times, the liposome particle size obtained is about 100 nm, surface is positive charge, meet the physical property requirement of respiratory mucosa immunity.The vaccine can be widely distributed in lung and long time retention after pulmonary mucosa route immunity, promote the uptake and activation of dendritic cell in lung to antigen, further activate T, B cell, produce mucosal immune response, and be taken up after dendritic cell, transport to lymph node, stimulate systemic adaptive immune response.The application provides effective mucosal immune vaccine platform for the prevention and treatment of respiratory pathogenic microorganism infection.

The invention relates to a process for the preparation of an extract obtained from undifferentiated cell suspension cultures of clary sage, to the extract obtained by this process, to the use of this extract as an active ingredient in the prevention and / or treatment of inflammation or microbial infections, to a pharmaceutical composition comprising said extract, to a sanitizing composition comprising said extract, to the use of said sanitizing composition for sanitizing a surface or increasing the surface's resistance to microbe transmission, to the cosmetic use of said extract as an anti-aging active ingredient and to a cosmetic composition comprising said extract

This document discloses methods and compositions for use in various therapeutic, preventive, and control measures comprising from about 0.00001% by weight to about 100% by weight of an extract derived from sugarcane. The therapeutic, preventive, and control measures involve administering the extract to a subject, the extract comprising from about 10 catechin equivalents (CE) g / L to about 50 CE g / L of polyphenols or from about 100 CE mg / g to about 500 CE mg / g of polyphenols. These therapeutic and preventive measures include antimicrobial activity, particularly against respiratory viruses in humans, and treatment of microsporidia infections, such as EHP in shrimp and prawns. Control measures include reducing methane production in ruminants. The use of these compositions in, for example, dairy cows improves cow health by minimizing mastitis while increasing milk yield.

The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and / or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections.

This disclosure relates to organophosphorous and organosulfurous compounds and their use in the amelioration, treatment, and / or prevention of microbial infections and diseases in a subject. The disclosure also relates to combination therapy using a composition comprising organophosphorous compounds, organosulfurous compounds, and antimicrobials in methods for treating or inhibiting microbial infections and diseases.

The invention relates an electrochemical biosensor for the quantification and endpoints use of Chrysophsin-1, -2 and -3 as biomarkers of welfare statute of lish. The innovation lies in a real time non-destructive method for the first stage alert of microbial infection or stress in fish, without prior extraction on the collected mucus. The approach being the monitoring of fish welfare. Thus, we have already demonstrated for the first time that the secretion of the antimicrobial peptides Chrysophsin-1, - 2 and -3 are an accurate marker for the fish welfare status, which is directly affected in the event of stress, disease or risk of infection by viruses, bacteria or parasites. Here we have built a biosensor capable of tracking and quantifying and storing the variations in the secretion levels of Chrysophsins. The method can be used as a point of care biosensor offering real-time secretion levels of Chrysophsins in mucus. The invention is also related to biosensor coatings including specific polyclonal antibody against the conserved Cterminus of Chrysophsin-1, -2 and -3 peptides. In some embodiments coating composition comprises a tether covalently attached to a polyclonal antibody anti-Chrysophsins; the tether allows the antibody to bind to the antimicrobial peptide present in the fish mucus. The polyclonal anti-Chrysophsin antibody is developed against the conserved C-terminus peptide of Chrysophsins-1, -2 and -3.

This invention relates to the field of pathogen infection detection technology, specifically a method for visually tracking human bronchial organoids infected with Mycoplasma pneumoniae. It includes the following steps: (1) Constructing human bronchial organoids: culturing mature human bronchial organoids with cavities, the organoids comprising ciliated cells, basal cells, goblet cells, and Club cells, having a polarized three-dimensional structure with the apex facing outwards; (2) Mycoplasma pneumoniae culture and fluorescent labeling: Mycoplasma pneumoniae is amplified and cultured in MP complete medium, and then fluorescently labeled using CellTrace far-infrared cell staining solution; (3) Co-culture for infection: Mycoplasma pneumoniae fluorescently labeled in step (2) is co-cultured with the human bronchial organoids from step (1) for infection; (4) Live cell dynamic fluorescence tracking: Non-invasive in situ continuous imaging is performed on the human bronchial organoids infected by MP in step (3). This invention can achieve non-invasive dynamic tracking of the entire process of MP infection.

The present document is directed to probiotic bacteria and their use in fish farming for increasing the weight of fish and for treating and / or preventing a microbial infection of the fish. The bacteria are species within the Aliivibrio, Psychrobacter and Pseudomonas genera.

The application provides a manganese-based organic framework and a preparation method and a drug delivery method thereof, wherein the manganese-based organic framework is generated through coordination connection of metal manganese ions and 1,1,2,2,-tetra(4-carboxyphenyl) ethylene ligands, the structure of the manganese-based organic framework is Mn2(TCPE)(H2O), wherein the TCPE is a fluorescent probe 1,1,2,2,-tetra(4-carboxyphenyl) ethylene. The manganese-based organic framework can be used as a nano-carrier with high drug loading capacity, can load active drug molecules with small and medium sizes, and can be used for treating cardiovascular diseases, cancers, microbial infections, wound healing, diabetes, senile dementia, tuberculosis and the like, and has no label and intrinsic fluorescence capacity, and can play a crucial role in actual experiments and interventions for detecting nano-carriers and rapidly tracking drugs.